title: Chemoprevention of experimental bladder cancer.
abstract: The chemopreventive efficacy of several compounds was evaluated in the N-butyl-N-(4-hydroxybutyl)nitrosamine (OH-BBN)-induced urinary bladder cancer model using C57BL/6 x DBA/2F1 (BDF) male mice. Compounds were administered in a defined semipurified diet (AIN-76-A) either as single agents or in combination. As single agents and at the doses employed, 2-alpha-difluoromethylornithine (DFMO), piroxicam, oltipraz, and sodium molybdate effectively inhibited the incidence of transitional cell carcinoma (TCC). 4-Hydroxyphenyl retinamide (4-HPR) was ineffective. Body weight gain and survival was not affected by the doses of agents used. Combinations of two agents which increased efficacy were 4-HPR+DFMO, DFMO+piroxicam, 4-HPR+oltipraz, and DFMO+oltipraz. Three-agent combinations which showed enhanced efficacy against TCC induction were 4-HPR+Na molybdate+DFMO, 4-HPR+DFMO+piroxicam, and 4-HPR+DFMO+oltipraz. Although the three-agent combinations were, for the most part, no more effective than the two-agent combinations at the doses employed, all combination regimens significantly reduced bladder cancer incidence even when single agent administration did not.
authors.affiliation: IIT Research Institute, Chicago, Illinois 60616.
authors.forename: R C
authors.initials: RC
authors.lastname: Moon
authors.forename: C J
authors.initials: CJ
authors.lastname: Detrisac
authors.forename: C F
authors.initials: CF
authors.lastname: Thomas
authors.forename: G J
authors.initials: GJ
authors.lastname: Kelloff
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D006801:Humans; D008297:Male; D001749:Urinary Bladder Neoplasms / Q000139:chemically induced / Q000517:prevention & control*
chemical_list: D000970:Antineoplastic Agents